

# Allergological Study in Patients Vaccinated Against COVID-19 with Suspected Allergic Reactions

Vicente Jover Cerdá (✉ [algena00@hotmail.com](mailto:algena00@hotmail.com))

Hospital General Universitario de Elda <https://orcid.org/0000-0002-2602-4532>

Ramón Rodríguez Pacheco

Hospital General Universitario de Elda

Joan Doménech Witek

Hospital General Universitario de Elda

Sonia Alonso Hernández

Hospital General Universitario de Elda

Rafael Durán García

Hospital General Universitario de Elda

Marina Real Panisello

Hospital General Universitario de Elda

Francisco Manuel Marco de la Calle

Hospital General Universitario de Elda

---

## Research

**Keywords:** anaphylaxis, basophil activation test, excipient allergy, hypersensitivity, polyethylene glycol, SARS-CoV-2, COVID-19 vaccines

**Posted Date:** February 9th, 2022

**DOI:** <https://doi.org/10.21203/rs.3.rs-1301307/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

## Abstract

# Background

One of the main barriers to vaccination against SARS-CoV-2 is the fear of developing hypersensitivity reactions to any of its components. Although these reactions are very rare, it is necessary to establish an effective protocol to detect patients at risk of developing them. The aim of this study was to evaluate hypersensitivity reactions in vaccinated patients in order to allow or not to complete the vaccination protocol.

## Methods

Descriptive and cross-sectional study in which patients with suspected hypersensitivity to SARS-CoV-2 vaccines were evaluated. All patients underwent skin prick test (SPT) and/or intradermal test (IDT) with the vaccines and their excipients. In patients with positive IDT with the vaccine, a histopathological and immunohistochemical study was performed by skin biopsy. A basophil activation test (BAT) and a lymphoblastic transformation test (LTT) were also performed.

## Results

Sixteen patients with suspected hypersensitivity to SARS-CoV-2 vaccine (12 received Comirnaty®, 3 received Vaxzevria®, and 1 received Spikevax®) were evaluated. Half had immediate hypersensitivity reactions and half had delayed reactions. All SPTs to excipients and vaccines were negative. IDTs with all excipients were negative. IDTs with vaccines were positive in 11 patients and negative in 5. The histological and immunohistochemical study of the two selected patients with positive IDT with vaccine showed T-lymphocyte involvement. BAT and LTT were negative in both cases. The vaccination protocol could be completed in 7 of 16 patients (44%) studied. The remaining 9 patients did not receive the second dose either because they already had the complete regimen or because they refused to be vaccinated.

## Conclusions

Thanks to the allergological and immunohistochemical study, the vaccination protocol could be completed in about half of the patients who presented suspected hypersensitivity reactions to SARS-CoV-2 vaccines. IDTs with vaccines could be a valuable method for assessing the immunogenicity of the vaccines.

## Background

2021 has become a year of hope for overcoming the pandemic initiated in 2019 by the SARS-CoV-2 coronavirus, thanks to the development of several safe and effective vaccines that have made it possible to reduce mortality, severe infection, and even virus transmission (1, 2). However, the implementation of the vaccination campaign has been marked by great fear of possible allergic reactions and negationism.

At the time of writing this article, the 4 types of vaccines authorized by the European Medicines Agency (EMA) have been used in Spain. According to the Spanish Agency for Medicines and Health Products (AEMPS), 82,518,671 doses had been administered: 91.7% with one dose or 89.7% with a complete regimen (December 17, 2021). Of the doses administered, 71% corresponded to Comirnaty® (BioNTech/Pfizer), 13% to Vaxzevria® (formerly COVID-19 Vaccine AstraZeneca), 13% to Spikevax® (formerly COVID-19 Vaccine Moderna), and 3% to COVID-19 Vaccine Janssen (3).

Most adverse effects following vaccination are due to a protective immune response induced by the vaccine and not to an allergic reaction (4). In fact, according to the literature reviewed, cases of immediate hypersensitivity (including anaphylaxis) and/or delayed hypersensitivity to SARS-CoV-2 vaccines are very rare. Even the etiopathogenic mechanism of allergic reactions to these vaccines is not clear. A meta-analysis stated that anaphylaxis with the vaccines against SARS-CoV-2 is a rare event, estimating 7.9 cases per million doses worldwide (5). According to the latest report of the Center for Disease Control and Prevention (CDC) of the

United States, 5.0 and 2.8 cases of anaphylaxis per million doses administered have been reported for patients vaccinated with Comirnaty® and Spikevax®, respectively (6). In Spain, the AEMPS has identified 8 cases (0.52%) with Comirnaty®, which represents a rate of 7.2 per million doses administered, mainly in women (88%) and with a median age of 33 years (7). In 5 of the cases (63%) there was a personal history of urticaria or drug or food allergy. Symptoms started within the first 30 minutes after vaccination and adrenaline was required in 75% of the cases (7).

In the first weeks after the start of vaccination, immediate hypersensitivity reactions were attributed to the excipients polyethylene glycol (PEG) and/or polysorbate 80 (PS80) used in most vaccines. In addition, it is important to note that both excipients have shown cross-reactivity (8, 9). However, reactions to these compounds are extremely rare and, if any, are due to non-IgE-mediated mechanisms (10). On the other hand, diagnoses of hypersensitivity to these polymers remain highly controversial, since skin tests with excipients of SARS-CoV-2 vaccines are not yet standardized and their efficacy, specificity, and sensitivity are questioned (1, 11). Several institutions, including the European Academy of Allergy and Clinical Immunology (EAACI), suggest performing skin tests with vaccines and their components in patients with suspected allergic reactions after the first dose (12). There are even authors who recommend intradermal test (IDT) with undiluted vaccine as it is not irritant (13, 14). Other authors do not recommend it because it may cause systemic reactions (15).

Sellaturay *et al.* confirmed the first case of anaphylaxis to Comirnaty® by a positive IDT with PS80 (16). Subsequently, isolated cases of immediate hypersensitivity and/or anaphylaxis by positive skin prick test (SPT) and/or positive IDT with PEG and/or PS80, and positive IDT with diluted and undiluted Comirnaty® have been published (17–21). Also noteworthy are the 17 cases diagnosed with anaphylaxis to Comirnaty® by positive basophil activation test (BAT) with the vaccine and PEG, and by negative skin tests with the vaccine components (10). In view of this information, the CDC, the EAACI, and the Spanish Society of Allergy and Clinical Immunology (SEAIC) contraindicate vaccination in patients with a history of immediate allergic reaction to the first dose of vaccine or to any of its excipients, especially to PEG in mRNA-based vaccines (Comirnaty® and Spikevax®) and to PS80 in adenovirus-based vaccines (Vaxzevria® and COVID-19 Vaccine Janssen) (6, 22–24).

Vaccination in the Health Department of Elda (Alicante, Spain) started on January 6, 2021. Until September 14, 2021, 282,064 doses were administered, of which 152,130 were the first dose and 129,905 the second dose. The most frequently used vaccine was Comirnaty® (218,950), followed by Vaxzevria® (37,771), Spikevax® (21,265), and COVID-19 Vaccine Janssen (4,050) (25).

The objective of this study was to describe and analyze the suspected hypersensitivity reactions in patients vaccinated with the first and/or second dose of SARS-CoV-2 vaccines, as well as to know the cause of these reactions among their components. We also evaluated whether these reactions interfered with the vaccination protocol.

## Methods

### Study design

Descriptive and cross-sectional study in which we evaluated all patients referred from the vaccination centers of the Health Department of Elda (Alicante, Spain) to the Allergology Unit with suspected hypersensitivity to SARS-CoV-2 vaccines, from January 6 to September 30, 2021. Patients who reported symptoms already described as side effects in the technical data sheet of the vaccines were discarded.

Primary objective was to evaluate immediate and/or delayed hypersensitivity reactions in patients vaccinated with the first and/or second dose of SARS-CoV-2 vaccines, in order to complete or not the vaccination protocol with the same vaccine or another alternative.

Secondary objectives were to know the clinical profile of vaccinated patients; immunohistochemical study of positive IDTs by skin biopsy; BAT and lymphoblastic transformation test (LTT) in patients with suspected hypersensitivity to the anti-SARS-CoV-2 vaccines; and the effect of allergic reactions on compliance with the vaccination protocol.

### Procedures

An anamnesis was performed on each of the selected patients, recording age, sex, personal history of atopy, type of vaccine administered, immediate and/or delayed symptoms after administration of the first and/or second dose of the vaccine, time interval between the administration of the vaccine and the reaction, treatment used after the reaction, and allergological study.

The skin tests were performed with leftover vaccine vials and with the excipients. For SPT, we used: undiluted vaccine; undiluted PEG300; PEG1500, PEG4000, and PEG6000 at 1% and 10%; Movicol® (PEG3350); Gastrografin® (EDTA and PS80); Trigon Depot® (PS80); Betadine Gel® (Macrogol 400, 4000, and 6000), Ultravist® (trometamol and EDTA); PS80 at 1% and 20%; trometamol in water 1:1; and EDTA at 0.3 mg/ml. For IDT, we used: vaccine undiluted and diluted at 1/100 and 1/10; PEG1500 and PEG4000 at 0.01%; PEG6000 at 1:10,000; Trigon Depot® at 1/10; Ultravist® at 1/10; PS80 at 1/1000 and 1/100; trometamol at 1/10; EDTA at 0.3 mg/ml. Both SPT and IDT with the excipients and the vaccine involved were performed in a stepwise manner from lower to higher concentration of the products, with reading at 30 minutes and at 24-48 hours. Histamine at 0.1% was used as a positive control in SPT and physiological serum at 0.9% as a negative control in SPT and IDT.

In patients with suspected delayed hypersensitivity, skin patch tests were performed with undiluted vaccine, PEG at 4%, and PS80 with reading at 72-96 hours. In addition, SPT and IDT were performed in 4 controls with immediate and delayed reading at all dilutions of the vaccines and excipients: 2 unvaccinated atopic patients (negative control in IDT with Comirnaty®), 1 atopic patient vaccinated with Comirnaty® without reaction (positive control in IDT with Comirnaty®), and 1 healthy unvaccinated patient (negative control in IDT with Vaxzevria®).

In patients with positive IDT with diluted and undiluted Comirnaty® vaccine, and in order to clarify whether it was an irritant response, a positive skin test suspicious for type IV hypersensitivity, or a T-cell mediated immune response for protection against SARS-CoV-2, we performed a histopathological and immunohistochemical study by skin biopsy of the IDT with the undiluted vaccine. In addition, BAT and LTT with peripheral blood mononuclear cells were performed.

BAT was performed by a commercial technique (Basotest®, Glycotope Biotechnology, Berlin Germany) using heparinized whole blood (9). Aliquots of blood were incubated with undiluted Comirnaty® and at 4 1/10 dilutions and basophil degranulation was determined through membrane-associated IgE, detecting surface CD63 expression.

LTT was performed to measure the cellular response to the vaccine by determining the proliferation of peripheral blood mononuclear cells by dilution of carboxyfluorescein-succinimidyl ester (CFSE) dye. This assay has been used previously for the analysis of cellular response to T-cell-mediated drug reactions (26). For proliferation assays with the vaccine, we used the same concentrations as in BAT.

According to the results obtained, in patients in whom hypersensitivity was ruled out, the vaccination protocol was completed, with or without a gradual schedule and premedication, with the second dose of the same vaccine or with an alternative vaccine. Vaccination was discarded in patients with suspected thromboembolic conditions or other disorders and/or severe allergic processes in whom hypersensitivity to the vaccine was demonstrated or in doubt.

## Ethics

The Drug Research Ethics Committee of the General University Hospital of Elda (Alicante, Spain) approved the study on November 26, 2021, with the protocol code VACUNALGUEÑA, VERSION 2.

In compliance with the Declaration of Helsinki and Good Clinical Practice and other regulations about personal data protection, all the information provided in this study was treated in accordance with confidentiality criteria.

Patients were informed about the details of the study for which they gave their consent to participate, according to recently published clinical practice (9, 12, 27).

## Results

A total of 24 patients were referred from the vaccination centers to the Allergy Unit with suspected hypersensitivity to the SARS-CoV-2 vaccines. Of these, 8 were discarded because they were considered to have side effects described in the technical data sheet of the vaccines; all tolerated the second dose without problems. Thus, 16 patients were evaluated: 11 women and 5 men

aged between 17 and 76 years (mean 52.6 years) (Table 1). Of the 16 patients studied, 12 received Comirnaty® (10 the first dose and 2 the two doses), 3 received Vaxzevria® (2 the first dose 1 the two doses), and 1 patient received Spikevax® (both doses). Ten of the patients had a history of atopy.

Table 1  
Clinical characteristics and allergological study of patients with suspected allergic reactions.

Patient N°	Age	Sex	Atopy	Vaccine (dose at which the reaction occurred)	Start of reaction	Signs and symptoms	Treatment prescribed	IDT with vaccine*	Continuation of the vaccination program
1	40	F	Yes	Comirnaty® (1st dose)	5'	Facial paresthesias with peribuccal burning and dizziness	Saline solution	1/100: + 1/10: + Undiluted: +	2nd dose Comirnaty®: YES (gradual with premedication)#
2	55	F	Yes	Comirnaty® (1st dose)	5'	Pruritus on the palate, dyspnea with 80% SatO <sub>2</sub> , generalized burning sensation, chronic diarrhea (3 months, from 10 days after vaccination).	IV corticoids IV and adrenaline	1/100: + 1/10: + Undiluted: +	2nd dose Comirnaty®: NO (refused vaccination)
3	73	M	Yes	Comirnaty® (1st dose)	> 24 h	Nausea and facial angioedema	IV corticoids and H1A	1/100: - 1/10: + Undiluted: +	2nd dose Comirnaty®: YES (gradual with premedication)#
4	73	M	Yes	Comirnaty® (1st dose)	> 24 h	Acute generalized urticaria	IV corticoids and H1A	1/100: - 1/10: - Undiluted: -	2nd dose Comirnaty®: YES
5	76	F	No	Comirnaty® (1st dose)	> 24 h	Generalized pruritus with dyspnea, abdominal swelling, ankle edema, possible subsegmental pulmonary thromboembolism, mild erythematous rash on arms and neckline.	IV corticoids and H1A	1/100: - 1/10: - Undiluted: -	2nd dose Comirnaty®: NO (refused vaccination)
6	68	M	No	Comirnaty® (1st dose)	60'	Wheals on upper limbs	No	1/100: - 1/10: - Undiluted: -	2nd dose Comirnaty®: YES
7	29	F	Yes	Comirnaty® (1st dose)	5'	Generalized erythematous rash with a few papules and facial angioedema, more intense at 24 h.	IV corticoids and H1A	1/100: + 1/10: + Undiluted: not done	2nd dose Comirnaty®: YES (gradual with premedication)#

\*The results for the 24 and 48 h readings were the same.

#Premedication consisted of chlorpheniramine 4 mg and prednisone 30 mg 13 hours and 1 hour before vaccination.

IV: intravenous; IM: intramuscular; H1A: H1-antihistamines; F: female; M: male

Patient N°	Age	Sex	Atopy	Vaccine (dose at which the reaction occurred)	Start of reaction	Signs and symptoms	Treatment prescribed	IDT with vaccine*	Continuation of the vaccination program
8	75	M	Yes	Comirnaty® (1st dose)	6 h	Red-vinous macules on lower limbs, upper limbs, thorax and back without itching of 3 weeks of evolution.	IM and oral corticoids and H1A	1/100: - 1/10: - Undiluted: -	2nd dose Comirnaty®: YES
9	58	F	Yes	Comirnaty® (1st and 2nd dose)	> 24 h	With the 1st dose, local swelling at 24 h and generalized urticaria at 48 h.  With 2nd dose, maculopapular rash and coldness in lower limbs.	H1A	1/100: - 1/10: + Undiluted: +	2nd dose Comirnaty®: NO (had passed COVID-19 two months before reaction)
10	51	F	No	Comirnaty® (1st dose)	5' y 24 h	At 5', erythematous rash on neckline  At 24 h, angioedema on the arms and hemiface	IV corticoids and H1A	1/100: + 1/10: + Undiluted: +	2nd dose Comirnaty®: YES (gradual with premedication)#
11	28	F	Yes	Comirnaty® (2nd dose)	10'	Pruritus of the tongue and throat, possible edema of the uvula and swelling of the neck.	IV and oral corticoids	1/100: - 1/10: + Undiluted: +	Not necessary (he received the two doses)
12	17	F	No	Comirnaty® (1st dose)	48 h	Wheals on the injection arm, fever and facial angioedema.	Oral corticoids and H1A	1/100: - 1/10: + Undiluted: +	2nd dose Comirnaty®: NO (had passed COVID-19 one month before reaction)
13	54	F	No	Spikevax® (2nd dose)	12-24 h	Fever, generalized urticaria and arthromyalgia.	H1A	1/100: - 1/10: + Undiluted: +	Not necessary (he received the two doses)
14	60	F	No	Vaxzevria® (1st dose)	30'	At 30', generalized erythematous and pruritic rash, dizziness and bruises on lower limbs.  At 17 days, post-vaccinal headache	IV corticoids, H1A and adrenaline	1/100: + 1/10: + Undiluted: +	2nd dose Comirnaty®: NO (refused vaccination)

\*The results for the 24 and 48 h readings were the same.

#Premedication consisted of chlorpheniramine 4 mg and prednisone 30 mg 13 hours and 1 hour before vaccination.

IV: intravenous; IM: intramuscular; H1A: H1-antihistamines; F: female; M: male

Patient N°	Age	Sex	Atopy	Vaccine (dose at which the reaction occurred)	Start of reaction	Signs and symptoms	Treatment prescribed	IDT with vaccine*	Continuation of the vaccination program
15	61	M	Yes	Vaxzevria® (1st and 2nd dose)	> 24 h	Acute urticaria-angioedema with both doses	IV corticoids and H1A	1/100: - 1/10: - Undiluted: -	Not necessary (he received the two doses)
16	24	F	Yes	Vaxzevria® (1st dose)	10' y < 24 h	At 10', abdominal pain, stridor and dyspnea.  At 28 days, dizziness, vomiting, facial paralysis, severe headache, numbness of lower limbs for < 24 h	IV corticoids and adrenaline	1/100: - 1/10: + Undiluted: +	2nd dose Vaxzevria®: NO (refused vaccination)
*The results for the 24 and 48 h readings were the same.									
#Premedication consisted of chlorpheniramine 4 mg and prednisone 30 mg 13 hours and 1 hour before vaccination.									
IV: intravenous; IM: intramuscular; H1A: H1-antihistamines; F: female; M: male									

## Hypersensitivity reactions

From the time the vaccines were administered, 8 patients had immediate hypersensitivity reactions (<60') and 8 patients had delayed reactions (>24 h). Two of the patients had both immediate and delayed reactions (Table 2). Symptoms were urticaria and/or angioedema, gastrointestinal, neurological, upper respiratory, lower respiratory, and cardiovascular. Most of them were mild to moderate. They were severe in 4 patients.

Table 2  
Results of skin tests with the responsible vaccines according to the type of symptoms

Symptoms	N° patients	Skin tests with vaccines			
		SPT +	SPT-	IDT + *	IDT -
Immediate	7	0	7	6	1
Delayed	7	0	7	3	4
Both	2	0	2	2	0
Total	16	0	16	11	5
IDT: intradermal test; SPT: skin prick test					
* all patients with positive IDT had positive results with the undiluted and 1/10 dilution vaccine. In 5 patients, IDT was positive with the 1/100 dilution. None had a systemic reaction with IDT.					

These reactions were treated with intravenous corticosteroids and adrenaline in 3 patients, corticosteroids (intravenous, intramuscular or oral) and H1-antihistamines in 9 patients, only H1-antihistamines in 2 patients, and only intravenous and oral corticosteroids in 1 patient. Two patients did not receive any treatment (Table 1).

## Skin tests, histological and immunohistochemical studies

The mean time elapsed between the hypersensitivity reaction and the skin tests was 42 days (7 to 147 days). In 11 patients the study was completed in less than 8 weeks.

All SPT with vaccines and excipients were negative, as well as skin patch tests performed in 7 delayed and 2 immediate reactions. Figure 1 shows some of the IDTs with Comirnaty®, Vaxzevria®, and Spikevax® and Table 2 shows the results of the skin tests with the responsible vaccine according to symptoms (11 positive IDT and 5 negative IDT). IDTs with all excipients were negative. In the 4 controls, all skin tests with the excipients were also negative.

Of all the patients with positive IDT with the vaccines, histological and immunohistochemical study was performed in two of them (since it is an invasive test, it was not performed in all of them due to ethical considerations). Histological and immunohistochemical study of positive IDT with undiluted Comirnaty® vaccine was performed in patient n°1 with reading at 24 hours (Figure 2) and at 48 hours in patient n°2 (Figure 3).

Histologic study of patient n°1 showed a mixed inflammatory infiltrate in the dermis, with perivascular and interstitial distribution, consisting predominantly of mature lymphocytes, in addition to some polynuclear neutrophils and isolated eosinophils and mast cells. The epidermis showed a slight vacuolar change of the focal basal layer (Figure 1A-C). In the histological study of patient n°2, a dermatitis with superficial and deep perivascular and interstitial distribution was observed. The inflammatory infiltrate was predominantly composed of mature lymphocytes with some eosinophils. In the lumen of some capillaries, some polymorphonuclear neutrophils could be recognized. The epidermis presented slight focal vacuolar change of the basal layer with scarce exocytosis of lymphocytes in the stratum basale (Figure 2A-B). Vasculitis was not seen in both patients. The results of the immunohistochemical study of both patients are shown in Figures 1D-F and Figure 2C-D.

BAT was negative in both cases to all dilutions of Comirnaty®, suggesting the absence of specific IgE to the vaccine components in the basophils of both patients. Likewise, no proliferation of the patients' lymphocytes was observed in response to the vaccine by LTT, so the vaccine components do not appear to be directly responsible for a cellular hypersensitivity reaction.

## Completion of the vaccination protocol

The vaccination protocol was completed in 7 of 16 (46%) patients (6 with Comirnaty® and 1 Spikevax®), 4 of them with a gradual schedule and premedication with good tolerance. The remaining 9 patients did not receive the second dose; 5 because they were fully vaccinated (4 has positive IDT and 1 had negative IDT) and 4 because they refused to be vaccinated due to fear or suspicion of thrombosis (3 had positive IDT and 1 had negative IDT). The 4 controls tolerated the corresponding vaccine.

## Discussion

Despite the different variants of SARS-CoV-2 that have been emerging since the beginning of the pandemic, or those that may appear in the near future, mass vaccination of the population is of vital importance to control both the harmful effects and the spread of the virus. However, fear of the occurrence of adverse events, especially hypersensitivity reactions, has triggered mistrust in the population. Although such reactions are rare, it is necessary to establish an effective protocol to detect patients at risk of developing them.

Concurrently to our study, similar studies have also been conducted in other regions of Spain and in other regions of the world with similar results (4, 19, 21, 28–35). After 282,064 doses administered during the period studied in our Health Department Area, we identified 16 (0.005%) patients with suspected hypersensitivity reaction to the vaccines (0.009% with Vaxzevria®, 0.004% with Spikevax®, and 0.007% with Comirnaty®), similar to that described by other authors with the first dose of Comirnaty® (28, 36, 37). It is important to highlight that most adverse events occurred in women, with a mean age of 52 years, and a history of previous allergic reactions.

Of the hypersensitivity reactions identified in our study, 8 were immediate reactions (6 mild and 3 severe) and 8 were delayed reactions (6 mild and 1 severe), especially cutaneous (urticaria and/or angioedema) and with the first dose of Comirnaty®. These findings were similar to those previously described. However, the form of presentation varied from one study to another. Loli-Ausejo *et al.* reported no anaphylaxis and attributed the symptoms to non-IgE-mediated mechanisms (28); the CDC reported 83 cases of mild cutaneous or respiratory reactions (0.0044%) and 21 cases of anaphylaxis with Comirnaty® (38); and Blumenthal *et al.*

described 1.95% of acute allergic reactions and a rate of 2.47 cases of anaphylaxis per 100,000 doses administered (35). In contrast, Shavit *et al.* observed that 98% of the 429 subjects who received a dose of Comirnaty® had no immediate allergic events, 1.4% had only minor allergic reactions, and 0.7% had anaphylactic reactions (39). There are other studies where only delayed reactions were described, due to a delayed type IV hypersensitivity mediated by T-cells (29, 32, 33).

We have observed that SPT with vaccine and SPT and IDT (immediate and delayed reading) with excipients have not been effective in the diagnosis of immediate or delayed hypersensitivity reactions, so that, as other authors believe, skin tests with excipients have very low sensitivity and specificity (1, 11). Some authors use Refrech Tears® (containing PS80) as a reagent, which has an irritant effect and is therefore not recommended (1, 11), but others believe that SPT with vaccine and excipients can be useful for diagnosis, despite the fact that in some of them the test was negative (28, 36, 37). Even so, there are isolated published cases of positive SPT with PEG6000 and positive IDT with Comirnaty® 1/100 dilution (21), and positive SPT with PS80 and Comirnaty®, without performing IDT (19), even positive SPT with PEG4000 at 1% with associated systemic reaction in which IDT is not recommended (15). Nevertheless, these studies attempted to complete the vaccination protocol, and the majority of patients tolerated the second doses, either fractionated or with premedication (20, 21). As in other studies, we have observed that skin patch tests with vaccine and excipients did not contribute to the diagnosis of delayed reactions, so it was recommended to complete the vaccination program, especially in cases of mild exanthema and large local reactions (29, 35).

In our study, attention was drawn to the 11 patients with positive IDT (6 with immediate reactions, 3 with delayed reactions, and 2 with both) at 24-48 hours with the vaccine diluted at 1/100, specially with the vaccine diluted at 1/10 or undiluted, without presenting associated systemic reaction. Some authors do not perform IDT when the SPT is positive with the vaccine or its excipients and others do not recommend it (15, 19, 28). According to some studies, IDT with Comirnaty® should not exceed 1/100 dilution to avoid irritant reactions or false positives, or even severe anaphylactic reactions (15, 21). However, others claim that SPT and IDT with Comirnaty® can be useful at 1/10 dilution and undiluted as they have been shown to be non-irritant in predicting immediate reactions (13, 14). Bianchi *et al.* also used IDT with Comirnaty® at 1/1000 and 1/100 dilution with positive results in 6 patients with mucous-cutaneous adverse reactions and in 12 vaccinated volunteers and negative in 6 unvaccinated volunteers, concluding that this may be a sign of cellular immune protection rather than an allergy to the SARS-CoV-2 spike protein or vaccine components (34). Turner *et al.* reported that the vaccine is capable of eliciting a delayed intradermal response in vaccinated subjects without PEG allergy (4). However, further studies are needed to investigate the usefulness of SPT and IDT with vaccines and to clarify the pathological mechanism of IDT reactions.

Interestingly, in contrast to LTT results, intradermal injection of the vaccine in the two patients selected for immunohistochemical study did produce a reaction involving T-lymphocytes; CD4 predominance in one case and a mixture of CD4 and CD8 in the other. This *in vivo* response could be due to the production of SARS-CoV-2 spike protein encoded by the vaccine-containing RNA, by antigen presenting cells of the skin, and by memory T-cells to peptides derived from this protein. Recent reports have described that in previously exposed patients, intradermal injection of recombinant spike protein induces a delayed-type hypersensitivity response involving T-lymphocytes (30, 31). The negativity of the *in vitro* cellular response could be due to the inefficiency of the liposomal vaccine construct to induce spike protein expression from the vaccine RNA under the culture conditions used, so that the vaccine components do not appear to be directly responsible for a cellular hypersensitivity reaction. BAT was negative in both cases to all dilutions of the vaccine, suggesting the absence of specific IgE to the vaccine components in the basophils of the two patients. Surprisingly, Warren *et al.* described 17 patients with anaphylaxis with positive BAT to vaccine and PEG and negative skin tests to vaccine components (10). The histological and immunohistochemical findings are similar to other published studies with large local reactions after administration of Spikevax®, using a single skin biopsy, but which have been considered as T-cell-mediated type IV delayed hypersensitivity reactions (32, 33). We wonder if in these cases, we are also facing a sign of protective cell-mediated immunity rather than a delayed type IV hypersensitivity reaction, considering that most of them tolerated the second doses (33).

According to the result of the 11 positive IDT and the immunohistochemical study in the 2 selected patients, in which we observed intense lymphocyte activity in the IDT with the undiluted vaccine, in addition to the negative result in LTT and BAT, and based on the bibliographic references consulted on the protective role of cellular immunity (4, 30, 31, 34), we decided to inoculate the second doses or an alternative vaccine in these patients, in order to ensure that the majority of them completed the vaccination protocol.

The main strength of the study is the clinical idea that justifies it, since the objective is to assess the impact of an interventional screening program in high-risk patients. However, due to the small number of patients, who belong to a very specific region, caution should be taken when extrapolating these results to the general population. Therefore, further studies with a larger population and a greater representation of all possible regions are needed.

## Conclusions

Thanks to the allergological and immunohistochemical study, we have been able to complete the vaccination protocol in about half of the patients who presented suspected hypersensitivity reactions. Hence the importance of the figure of the allergist together with other specialties in the resolution of problems regarding hypersensitivity reactions with anti-SARS-CoV-2 vaccines, given that the objective is to ensure that a large majority of the population completes the vaccination protocol. On the other hand, the finding of IDTs with the vaccines themselves could constitute a valuable method for assessing the immunogenicity of the vaccines, although it would be necessary to define the specificity of the response evoked by the inoculum; either some component of the vaccine or the SARS-CoV-2 antigen encoded by the vaccine.

## List Of Abbreviations

AEMPS

Spanish Agency for Medicines and Health Products

BAT

basophil activation test

CDC

Center for Disease Control and Prevention

EAACI

European Academy of Allergy and Clinical Immunology

EMA

European Medicine Agency

IDT

intradermal test

LTT

lymphoblastic transformation test

PEG

polyethylene glycol

PS80

polysorbate 80

SEAIC

Spanish Society of Allergy and Clinical Immunology

SPT

skin prick test

## Declarations

### Ethic approval and consent to participate

The Drug Research Ethics Committee of the General University Hospital of Elda (Alicante, Spain) approved the study on November 26, 2021, with the protocol code VACUNALGUEÑA, VERSION 2.

Patients were informed about the details of the study for which they gave their consent to participate, according to recently published clinical practice

### Consent for publication

Patients were informed that the results of the study were going to be published and gave their consent.

### **Availability of data and materials**

Not applicable.

### **Competing interests**

The authors declare that they have no competing interests.

### **Funding**

The study did not receive any funding.

### **Authors' contributions**

VJC designed the study, performed the skin prick test and the intradermal test, analyzed and interpreted the patient data, and was a major contributor in writing the manuscript.

RRP performed the skin prick test and the intradermal test.

JDW performed the skin prick test and the intradermal test.

SAH performed the histological and immunohistochemical tests.

RDG performed the histological and immunohistochemical tests.

MRP prepared the dilutions of the vaccines and excipient.

FMMC performed the lymphoblastic transformation test and the basophil activation test.

All authors read and approved the final manuscript.

### **Acknowledgements**

The authors wish to thank Fernando Sánchez Barbero PhD for his help in the preparation of the manuscript. In addition, we thank the nursing staff of the Allergy Unit and the staff of the Pharmacy Service of the General University Hospital of Elda.

## **References**

1. Greenhawt M, Shaker M, Golden DBK. PEG/Polysorbate Skin Testing Has No Utility in the Assessment of Suspected Allergic Reactions to SARS-CoV-2 Vaccines. *J Allergy Clin Immunol Pract.* 2021;9(9):3321–2.
2. Shah ASV, Gribben C, Bishop J, Hanlon P, Caldwell D, Wood R, et al. Effect of Vaccination on Transmission of SARS-CoV-2. *N Engl J Med.* 2021;385(18):1718–20.
3. Agencia Española de Medicamentos y Productos Sanitarios. 11º Informe de Farmacovigilancia sobre Vacunas COVID-19 [cited 2021 January 2022]. Available from: <https://www.aemps.gob.es/informa/boletines-aemps/boletin-fv/2021-boletin-fv/11o-informe-de-farmacovigilancia-sobre-vacunas-covid-19/>.
4. Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, et al. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. *World Allergy Organ J.* 2021;14(2):100517.
5. Greenhawt M, Abrams EM, Shaker M, Chu DK, Khan D, Akin C, et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. *J Allergy Clin Immunol Pract.* 2021;9(10):3546–67.
6. Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. *JAMA.* 2021;325(11):1101–2.

7. Agencia Española de Medicamentos y Productos Sanitarios. 2º Informe de Farmacovigilancia sobre Vacunas COVID-19 [cited 2021 December 12]. Available from: <https://www.aemps.gob.es/informa/boletines-aemps/boletin-fv/2021-boletin-fv/2o-informe-de-farmacovigilancia-sobre-vacunas-covid-19/>.
8. Huynh VA, Janssen C, Beaumier L. [ARN COVID-19 COMIRNATY Vaccine desensitization in a case of PEG Severe Immediate Hypersensitivity]. *Rev Fr Allergol* (2009). 2021.
9. Jover Cerda V, Rodriguez Pacheco R, Domenech Witek J, Marco de la Calle FM, de la Sen Fernandez ML. Immediate hypersensitivity to polyethylene glycols in unrelated products: when standardization in the nomenclature of the components of drugs, cosmetics, and food becomes necessary. *Allergy Asthma Clin Immunol*. 2019;15:9.
10. Warren CM, Snow TT, Lee AS, Shah MM, Heider A, Blomkalns A, et al. Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. *JAMA Netw Open*. 2021;4(9):e2125524.
11. Wolfson AR, Robinson LB, Li L, McMahon AE, Cogan AS, Fu X, et al. First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing. *J Allergy Clin Immunol Pract*. 2021;9(9):3308–20 e3.
12. Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. *Allergy*. 2021;76(6):1629–39.
13. Vieira J, Marcelino J, Ferreira F, Farinha S, Silva R, Proenca M, et al. Skin testing with Pfizer SARS-CoV-2 vaccine and PEG 2000. *Asia Pac Allergy*. 2021;11(2):e18.
14. Marcelino J, Farinha S, Silva R, Didenko I, Proenca M, Tomaz E. Nonirritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine. *J Allergy Clin Immunol Pract*. 2021;9(6):2476–7.
15. Sellaturay P, Nasser S, Islam S, Gurugama P, Ewan PW. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. *Clin Exp Allergy*. 2021;51(6):861–3.
16. Sellaturay P, Nasser S, Ewan P. Polyethylene Glycol-Induced Systemic Allergic Reactions (Anaphylaxis). *J Allergy Clin Immunol Pract*. 2021;9(2):670–5.
17. Paoletti G, Racca F, Piona A, Melone G, Merigo M, Puggioni F, et al. Successful SARS-CoV-2 vaccine allergy risk-management: The experience of a large Italian University Hospital. *World Allergy Organ J*. 2021;14(5):100541.
18. Habran M, Vandebotermert M, Schrijvers R. Polyethylene glycol allergy and immediate-type hypersensitivity reaction to COVID-19 vaccination: case report. *J Investig Allergol Clin Immunol*. 2021:0.
19. Perez-Codesido S, Rosado A, Alonso-Diaz-de-Durana MD, Alfaya Arias T, Gonzalez-Moreno A, Tejedor Alonso MA. Hypersensitivity to COVID-19 Vaccine Confirmed by a Positive Skin Test Result: A Case Report. *J Investig Allergol Clin Immunol*. 2021:0.
20. Anton Girones M, Montoro Lacomba J, Navarro Cascales T, Lindo Gutarra M, Marco de la Calle FM. Administration of the Comirnaty(R) Vaccine in a Fractional Regimen in Two Patients with Immediate Acute Urticaria after the First Dose. *J Investig Allergol Clin Immunol*. 2021:0.
21. Pickert J, Hennighausen I, Muhlenbein S, Mobs C, Pfutzner W. Immediate-Type Hypersensitivity to Polyethylene Glycol (PEG) and a PEG-Containing COVID-19 Vaccine Revealed by Intradermal Testing. *J Investig Allergol Clin Immunol*. 2021;31(6):526–7.
22. Klimek L, Jutel M, Akdis CA, Bousquet J, Akdis M, Torres MJ, et al. ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - An EAACI-ARIA Position Paper. *Allergy*. 2021;76(6):1624–8.
23. Sociedad Española de Alergología e Inmunología Clínica. Comunicado vacuna COVID-19 de Pfizer en alérgicos [cited 2021 December 12]. Available from: <https://www.seaic.org/inicio/noticias-general/comunicado-vacuna-covid-19-de-pfizer-en-alergicos.html>.
24. Ortega Rodriguez NR, Audicana Berasategui MT, de la Hoz Caballer B, Valero Santiago A. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy. *J Investig Allergol Clin Immunol*. 2021;31(1):89–91.
25. Conselleria de Sanitat Universal i Salut Pública. COVID-19 Comunitat Valenciana: Monitoratge de la situació [cited 2021 December 12]. Available from: <https://icvgva.maps.arcgis.com/apps/opsdashboard/index.html#/3a3115ad642a4516b0928f21e395b32d>.
26. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. *Allergy*. 2004;59(8):809–20.
27. Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. *Clin Exp Allergy*. 2016;46(7):907–22.

28. Loli-Ausejo D, Gonzalez de Abreu JM, Fiandor A, Cabanas R, Dominguez-Ortega F, Caballero ML, et al. Allergic Reactions After Administration of Pfizer-BioNTech COVID-19 Vaccine to Health Care Workers at a Tertiary Hospital. *J Investig Allergol Clin Immunol*. 2021;31(6):507–8.
29. Juarez Guerrero A, Dominguez Estirado A, Crespo Quiros J, Rojas-Perez-Ezquerria P. Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19. *J Allergy Clin Immunol Pract*. 2021;9(10):3811–3.
30. Barrios Y, Franco A, Sanchez-Machin I, Poza-Guedes P, Gonzalez-Perez R, Matheu V. A novel application of delayed-type hypersensitivity reaction to measure cellular immune response in SARS-CoV-2 exposed individuals. *Clin Immunol*. 2021;226:108730.
31. Barrios Y, Franco A, Sanchez-Machin I, Poza-Guedes P, Gonzalez-Perez R, Matheu V. The Beauty of Simplicity: Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Responses in RNA-SARS-Cov-2 Vaccinated Individuals. *Vaccines (Basel)*. 2021;9(6).
32. Johnston MS, Galan A, Watsky KL, Little AJ. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series. *JAMA Dermatol*. 2021;157(6):716–20.
33. Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, et al. Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2. *N Engl J Med*. 2021;384(13):1273–7.
34. Bianchi L, Biondi F, Hansel K, Murgia N, Tramontana M, Stingeni L. Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing. *Allergy*. 2021;76(8):2605–7.
35. Blumenthal KG, Robinson LB, Camargo CA Jr, Shenoy ES, Banerji A, Landman AB, et al. Acute Allergic Reactions to mRNA COVID-19 Vaccines. *JAMA*. 2021;325(15):1562–5.
36. Valente C, Miranda G, Aguiar A, Silva P, Santa C, Mesquita M, et al. Pfizer-BioNTech COVID-19 vaccine: Suspected allergic reactions to the first dose. *Allergy: European Journal of Allergy Clinical Immunology*. 2021;76(Suppl 110):475–6.
37. Sucre-Adrianza I, García-Vila H, García-Zaragoza MDR, González ML, Sánchez-Morillas L, Robledo T, et al. Hypersensitivity reactions to Pfizer-BioNTech COVID-19 vaccine in the staff of Hospital Clínico San Carlos in Madrid, Spain *Allergy: European Journal of Allergy Clinical Immunology*. 2021;76(Suppl 110):650.
38. CDC COVID-19 Response Team, Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020. *MMWR Morb Mortal Wkly Rep*. 2021;70(2):46–51.
39. Shavit R, Maoz-Segal R, Iancovici-Kidon M, Offengenden I, Haj Yahia S, Machnes Maayan D, et al. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk. *JAMA Netw Open*. 2021;4(8):e2122255.

## Figures



Patient n°1, Comirnaty®, 24 h

Patient n°2, Comirnaty®, 48 h

Patient n°11, Comirnaty®, 24 h

Control patient,  
Comirnaty®



Patient n°16, Vaxzevria®, 24 h



Patient n°13, Spikevax®,  
24 h, undiluted




Paciente n°13, Spikevax®,  
24 h, 1/10 dilution


Figure 1

IDT with Comirnaty®, Vaxzevria® and Spikevax®


F or SF: control with saline solution; Vp: undiluted vaccine; V<sub>1/100</sub>: 1/100 diluted vaccine; V<sub>1/10</sub>: 1/10 diluted vaccine




**Hematoxylin-eosin 10x**  
Dermatitis with superficial and deep perivascular distribution




**Hematoxylin-eosin 40x**  
Inflammatory infiltrate in the dermis with a predominance of mature lymphocytes




**Hematoxylin-eosin 10x**  
Foci of inflammation in adipose tissue, composed of polymorphonuclear neutrophils and lymphocytes



**Immunohistochemistry 10x**  
Immunohistochemical study of lymphocyte cellularity with CD3 positivity




**Immunohistochemistry 10x**  
Immunohistochemical analysis of lymphocyte cellularity for CD4 and CD8, with CD4 predominating




**Figure 2**


Histological and immunohistochemical study of patient n°1




**Hematoxylin-eosin 10x**  
Dermatitis with superficial and deep perivascular and interstitial distribution



**Hematoxylin-eosin 40x**  
Inflammatory infiltrate of perivascular distribution, with a predominance of mature lymphocytes



**Immunohistochemistry 10x**  
Inflammatory infiltrates of CD3-positive lymphocytes



**Immunohistochemistry 10x**  
Lymphocytes are positive for CD4 and CD8 in similar proportions

**Figure 3**

Histological and immunohistochemical study of patient n°2